MDElliottMD: Create Cannabigerol (CBG) medicine stub: minor phytocannabinoid, biosynthetic precursor from CBGA to THCA/CBDA/CBCA, non-psychoactive, multiple non-CB pharmacology targets. Cites Russo 2011 (PMID 21749363).

2026-05-19T06:22:21Z

Create Cannabigerol (CBG) medicine stub: minor phytocannabinoid, biosynthetic precursor from CBGA to THCA/CBDA/CBCA, non-psychoactive, multiple non-CB pharmacology targets. Cites Russo 2011 (PMID 21749363).

New page

{{Stub}}
{{MedTemplate
| generic = Cannabigerol
| classes = Cannabinoid (minor), phytocannabinoid, precursor cannabinoid
| mechanism = Weak partial agonist at CB1 and CB2; alpha-2 adrenergic agonist; 5-HT1A antagonist; multiple TRP channel effects.
| intro = '''Cannabigerol''' (CBG) is a minor phytocannabinoid of [[Cannabis|cannabis]] and, in its acidic form cannabigerolic acid (CBGA), the biosynthetic precursor from which the plant produces [[THC|tetrahydrocannabinolic acid]] (THCA), [[CBD|cannabidiolic acid]] (CBDA), and cannabichromenic acid (CBCA) by enzyme-specific cyclization. Mature flower typically contains less than 1% CBG because most CBGA has already been converted into the downstream cannabinoids; CBG-dominant chemovars (the chemovar type IV classification) are an exception. CBG is non-psychoactive at typical doses and has weak direct cannabinoid-receptor activity; its preclinical pharmacology is dominated by non-CB targets including alpha-2 adrenergic agonism, 5-HT1A antagonism, and modulation of TRPM8 and TRPV channels. Clinical evidence remains preliminary; CBG-rich extracts have been investigated for inflammatory bowel disease, glaucoma, and antibacterial activity, but no CBG-containing product has been approved for any indication.<ref name="russo2011-entourage">Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. ''Br J Pharmacol''. 2011 Aug;163(7):1344-64. PMID: 21749363.</ref>
}}

[[Category:Cannabinoids]]

CBG - Revision history

MDElliottMD: Create Cannabigerol (CBG) medicine stub: minor phytocannabinoid, biosynthetic precursor from CBGA to THCA/CBDA/CBCA, non-psychoactive, multiple non-CB pharmacology targets. Cites Russo 2011 (PMID 21749363).